ClinicalTrials.gg
CompletedNCT06373146Updated May 6, 2026

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

A Phase 2 interventional study of Tirzepatide and Mibavademab in Obesity, sponsored by Eli Lilly and Company. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
45th of 117
392 · median 267
Started
2024
with 19 others
Phase 2
22 of 118
5 open now
Registered
50th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 45th largest by enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 22 in phase 2, and was the 50th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Glucagon-like peptide-1 (GLP-1)
  • Leptin
  • Incretin
  • Weight maintenance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m²
  • Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention)
  • Male or female use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma
  • Have a self-reported change (increase or decrease) in body weight >5 kilogram (kg) within 3 months prior to screening
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2
  • Have acute or chronic hepatitis
  • Have a history of an active or untreated or are in remission from a malignancy for less than 5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]

    Participants will receive TZP subcutaneously (SC) and MIBA for 24 weeks. Participants in Group A will be randomized (Randomization 2) to groups C and D at week 24.

    Drug: Tirzepatide · Drug: Mibavademab

  • Experimental
    TZP + Mibavademab-placebo (MIBA-PBO) [Group B]

    Participants will receive TZP SC and MIBA-PBO SC for 24 weeks. Participants in Group B will be randomized (Randomization 2) to Groups E, F, G, and H at week 24.

    Drug: Tirzepatide · Drug: Mibavademab-Placebo

  • Experimental
    TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]

    Participants will receive TZP SC and MIBA SC for 24 weeks followed by TZP-PBO SC and MIBA SC for 24 weeks.

    Drug: Tirzepatide · Drug: Mibavademab · Drug: Tirzepatide-Placebo

  • Experimental
    TZP + MIBA [Group D]

    Participants will receive TZP SC + MIBA SC for 48 weeks.

    Drug: Tirzepatide · Drug: Mibavademab

  • Experimental
    TZP + MIBA-PBO [Group E]

    Participants will receive TZP SC + MIBA-PBO SC for 48 weeks.

    Drug: Tirzepatide · Drug: Mibavademab-Placebo

  • Experimental
    TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]

    Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA SC for 24 weeks.

    Drug: Tirzepatide · Drug: Mibavademab · Drug: Tirzepatide-Placebo · Drug: Mibavademab-Placebo

  • Experimental
    TZP + MIBA-PBO then TZP + MIBA [Group G]

    Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP SC + MIBA SC for 24 weeks.

    Drug: Tirzepatide · Drug: Mibavademab · Drug: Mibavademab-Placebo

  • Experimental
    TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]

    Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA-PBO SC for 24 weeks.

    Drug: Tirzepatide · Drug: Tirzepatide-Placebo · Drug: Mibavademab-Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • Administered SC

    Also known as: REGN4461

  • DrugTirzepatide-Placebo

    Administered SC

  • DrugMibavademab-Placebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Mean Change from Baseline for Percent Change and Absolute Change in Body Weight (kg)

    Time frame: Baseline, Week 24

  2. Mean Absolute Change from Baseline for Body Weight (kg)

    Time frame: Baseline, Week 48

  3. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Time frame: Baseline to Week 48

  4. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Time frame: Baseline to Week 48

  5. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Time frame: Baseline to Week 48

  6. Percentage of Participants Who Achieve ≥20 Body Weight Reduction

    Time frame: Baseline to Week 48

  7. Mean Percent Change from Randomization 2 for Body Weight

    Time frame: Week 24, Week 48

  8. Mean Change from Randomization 2 for Body Weight (kg)

    Time frame: Week 24, Week 48

  9. Mean Absolute Change from Randomization 2 for Body Weight (kg)

    Time frame: Week 24, Week 48

  10. Change from Baseline to Week 24 in CoEQ Scores

    Time frame: Baseline, Week 24

  11. Change from Baseline to Week 48 in CoEQ Scores

    Time frame: Baseline, Week 48

  12. Change from Baseline in FCQ-T-r Scores

    Time frame: Baseline, Week 24

  13. Change from Baseline in FCQ-T-r Scores

    Time frame: Baseline, Week 48

07

Study locations

17 sites
  • Velocity Clinical Research, Gardena
    Gardena, California 90247, United States
  • Irvine Clinical Research
    Irvine, California 92614, United States
  • Velocity Clinical Research, Los Angeles
    Los Angeles, California 90017, United States
  • Velocity Clinical Research, North Hollywood
    North Hollywood, California 91606, United States
  • Velocity Clinical Research, Santa Ana
    Santa Ana, California 92704, United States
  • Velocity Clinical Research, Panorama City
    Van Nuys, California 91405, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Velocity Clinical Research - New Orleans
    New Orleans, Louisiana 70119, United States
  • Hassman Research Institute Marlton Site
    Marlton, New Jersey 08053, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • South Texas Clinical Research
    Corpus Christi, Texas 78404, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Dec 2025, 19 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 19 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 18, 2024
StartActual
Apr 24, 2024
Primary completionActual
Dec 15, 2025
CompletionActual
Apr 2, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373146
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Apr 24, 2024
Primary completion
Dec 15, 2025
Completion
Apr 2, 2026
Last update
May 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion